GB485569A - Process for the manufacture of stable solutions of the polyoxyalkylisoalloxazines - Google Patents

Process for the manufacture of stable solutions of the polyoxyalkylisoalloxazines

Info

Publication number
GB485569A
GB485569A GB3146636A GB3146636A GB485569A GB 485569 A GB485569 A GB 485569A GB 3146636 A GB3146636 A GB 3146636A GB 3146636 A GB3146636 A GB 3146636A GB 485569 A GB485569 A GB 485569A
Authority
GB
United Kingdom
Prior art keywords
mixture
water
amide
glycol
methylacetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB3146636A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IG Farbenindustrie AG
Original Assignee
IG Farbenindustrie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IG Farbenindustrie AG filed Critical IG Farbenindustrie AG
Priority to GB3146636A priority Critical patent/GB485569A/en
Publication of GB485569A publication Critical patent/GB485569A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/12Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C07D475/14Benz [g] pteridines, e.g. riboflavin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

9 - Polyhydroxyalkyl - isoalloxazines are solubilized by means of an N-alkylamide of an aliphatic acid containing not more than six carbon atoms, the amide being used in liquid form. The solutions are useful therapeutically. When the amide is not itself liquid, it may be liquefied by means of water or other solvent such as glycol, propylene-glycol or butylene-glycol, or by p admixture with another solid or liquid N-alkylamide or another amide. According to the examples, (1) lactoflavin, i.e. 9-d-ribityl-6 : 7-dimethyl-isoalloxazine (vitamin B2 or G), is dissolved in a mixture of N-methylacetamide and water, a mixture in equal parts by weight of N-methyl- and ethyl-acetamides, a mixture of N-(b -hydroxyethyl)-acetamide and water, a mixture of N - (b - acetylamino - ethyl) - acetamide and water, a mixture of N-hydroxyethyl-lactic acid amide and water, a saturated aqueous solution of oxalic acid-bis-hydroxyethylamide, a mixture of N-b -hydroxyethylpropionic acid amide and water, a mixture of sarcosine anhydride and water, and a mixture of N-methylacetamide and 1 : 2 - propylene - glycol; (2) 6 : 7-dimethyl-9-l-arabityl-isoalloxazine is dissolved in a mixture of N-methylacetamide and water. Acid amides.-N - hydroxyethyl - lactic acid amide is prepared by boiling lactic acid ethyl ester with ethanolamine. N-b -hydroxy-ethyl-propionic acid amide is similarly obtained using propionic acid ethyl ester.ALSO:9 - Polyhydroxyalkyl - isoalloxazines are solubilized by means of an N-alkylamide of an aliphatic acid containing not more than six carbon atoms, the amide being used therapeutically in liquid form. When the amide is not itself liquid, it may be liquefied by means of water or other solvent such as glycol, propylene-glycol or butylene-glycol, or by admixture with another solid or liquid N-alkylamide or another amide. According to the examples, (1) lactoflavin, i.e. 9-d-ribityl-6 : 7-dimethylisoalloxazine (vitamin B2 or G), is dissolved in a mixture of N-methylacetamide and water, a mixture in equal parts by weight of N-methyl- and ethyl-acetamides, a mixture of N-(b -hydroxyethyl)acetamide and water, a mixture of N-(b -acetylaminoethyl)-acetamide and water, a mixture of N-hydroxyethyl-lactic acid amide and water, a saturated aqueous solution of oxalic acid-bis-hydroxyethylamide, a mixture of N-b -hydroxyethyl-propionic acid amide and water, a mixture of sarcosine anhydride and water, and a mixture of N-methylacetamide and 1 : 2-propylene-glycol; (2) 6 : 7-dimethyl-9-l-arabityl-isoalloxazine is dissolved in a mixture of N-methylacetamide and water.
GB3146636A 1936-11-17 1936-11-17 Process for the manufacture of stable solutions of the polyoxyalkylisoalloxazines Expired GB485569A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB3146636A GB485569A (en) 1936-11-17 1936-11-17 Process for the manufacture of stable solutions of the polyoxyalkylisoalloxazines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB3146636A GB485569A (en) 1936-11-17 1936-11-17 Process for the manufacture of stable solutions of the polyoxyalkylisoalloxazines

Publications (1)

Publication Number Publication Date
GB485569A true GB485569A (en) 1938-05-17

Family

ID=10323503

Family Applications (1)

Application Number Title Priority Date Filing Date
GB3146636A Expired GB485569A (en) 1936-11-17 1936-11-17 Process for the manufacture of stable solutions of the polyoxyalkylisoalloxazines

Country Status (1)

Country Link
GB (1) GB485569A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2445208A (en) * 1946-02-04 1948-07-13 Wyeth Corp Solutions of riboflavin
US2571326A (en) * 1950-01-31 1951-10-16 Hoffmann La Roche Aqueous solutions of riboflavin
US2671748A (en) * 1950-05-18 1954-03-09 Parke Davis & Co Composition of matter
US3075882A (en) * 1960-03-16 1963-01-29 Upjohn Co Estrone solubilized with n, n-dimethylacetamide
US3142617A (en) * 1959-07-15 1964-07-28 Ciba Geigy Corp Injectable solution
US3443004A (en) * 1965-04-08 1969-05-06 Ciba Geigy Corp Injectable solution containing 6-chloroor 6-trifluoromethyl-7-sulfamyl - 1,2,4-benzothiodiazine-1,1-dioxide diuretic
EP2184066A1 (en) * 2007-09-04 2010-05-12 Meiji Seika Kaisha Ltd. Injection, injection solution and injection kit preparation

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2445208A (en) * 1946-02-04 1948-07-13 Wyeth Corp Solutions of riboflavin
US2571326A (en) * 1950-01-31 1951-10-16 Hoffmann La Roche Aqueous solutions of riboflavin
US2671748A (en) * 1950-05-18 1954-03-09 Parke Davis & Co Composition of matter
US3142617A (en) * 1959-07-15 1964-07-28 Ciba Geigy Corp Injectable solution
US3075882A (en) * 1960-03-16 1963-01-29 Upjohn Co Estrone solubilized with n, n-dimethylacetamide
US3443004A (en) * 1965-04-08 1969-05-06 Ciba Geigy Corp Injectable solution containing 6-chloroor 6-trifluoromethyl-7-sulfamyl - 1,2,4-benzothiodiazine-1,1-dioxide diuretic
EP2184066A1 (en) * 2007-09-04 2010-05-12 Meiji Seika Kaisha Ltd. Injection, injection solution and injection kit preparation
EP2184066A4 (en) * 2007-09-04 2012-08-01 Meiji Seika Kaisha Injection, injection solution and injection kit preparation

Similar Documents

Publication Publication Date Title
GB478326A (en) Improvements in the manufacture of ketene, acetic anhydride or a homologue thereof
GB841751A (en) Improvements in or relating to herbicidal compositions of matter
GB911185A (en) Electrically conductive compositions
GB485569A (en) Process for the manufacture of stable solutions of the polyoxyalkylisoalloxazines
ES470296A1 (en) Fluorinated amino acids
GB478325A (en) Improvements in the manufacture of ketene, acetic anhydride or a homologue thereof
Kirby In vitro action of urea-sulfonamide mixtures
GB643765A (en) Improvements relating to emulsions of saturated fatty acids
GB713720A (en) Improvements in or relating to the preparation of stabilized liquid catalase
GB951663A (en) Process for the preparation of 6-deoxy-6-demethyl-6-methylene-5-oxytetracycline
GB530269A (en) Improvements in or relating to the manufacture of the nitriles of organic carboxylicacids
GB976393A (en) Pharmaceutical compositions comprising solutions of salicylamide
GB570271A (en) Improvements in or relating to the manufacture of carboxylic acid anhydrides
GB805951A (en) Improvements in the production of alpha. beta-dichlorpropionic acid esters
GB602078A (en) Manufacture of stable supersaturated solutions of saccharide derivatives of compounds of the suprarenal cortex hormone series
GB465331A (en) Manufacture of new esters of polynuclear cyclic oxyketones
GB729550A (en) A process for preparing cyclohexyl esters of ª‰-phenyl-ª‡-amino acids, and new products obtained thereby
GB829029A (en) Preparation of cyanoformamide
GB537712A (en) Process for the production of aliphatic acids from their salts
GB1252069A (en)
GB450357A (en) Manufacture of chromiferous dyestuffs
GB624136A (en) Process for stabilising dichlorodiphenyltrichloroethane
GB384403A (en) Process for increasing the affinity of cellulose esters for dyestuffs
SENDO ABOUT THE THEORY OF CELLULOSE NITRATION.
GB440344A (en) Manufacture of 4-nitroso-diphenylamine derivatives